Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 10 December 2019, 08:02 HKT/SGT
Share:
    

Source: Eisai
Commencement of Major Renovation of Tsukuba Research Laboratories as Eisai Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and the World

TOKYO, Dec 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai had a groundbreaking ceremony for a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan) as part of strategic investment to realize Eisai's medium-term business plan "EWAY2025."

Since the opening in 1982, the Tsukuba Research Laboratories has led the creation of innovation by discovering the cutting-edge drugs including Aricept, Pariet, Lenvima and Fycompa over the last approximate 40 years. In order for the Tsukuba Research laboratories to continue to play the central role also in the next generation innovation creation as Eisai's global drug discovery center, a major renovation is conducted with a key concept "Human Connected Laboratories: Laboratories Connecting Human and Human, and Data, and the World." This renovation aims to accelerate the further knowledge circulation by connecting each researcher with patients, other members at the Tsukuba Research Laboratories, the research sites in the world, and external researchers, as well as developing the environment for the further digitalization era.

[Connection with Patients]
In the Eisai Group, all employees around the world using 1% of their total business hours to interact with patients (socialization) to understand the thoughts and feelings of patients. Accordingly, we have been working on the initiatives (hhc activities) for leading to the creation of values for patients.

The facility is established for enhancing communication by developing new places and spaces for closer socialization with patients at the Tsukuba Research Laboratories.

[Connection with Other Members at Tsukuba Research Laboratories]
In order to accelerate the knowledge exchange in the Tsukuba Research Laboratories and to support the workstyle to increase the researchers' efficiency, the renovation for improving the traffic lines between workspaces or research buildings, as well as building the spaces for various co-creation is conducted.

[Connection with the World]
The facility and equipment for accelerating the interactions with our partners are also developed while developing the environment of meeting rooms for smooth communication with overseas bases.

[Connection with Data]
The facilities with safety, extensibility, and variability for further data-driven and digitalization are built while renovating to enable the equipment layout to accelerate the effective usage of all research equipment of Tsukuba Research Laboratories.

In consideration of the environment, this construction is conducted as a renovation for more effective use of resources in comparison with demolition and new construction. Eisai is also planning to introduce an energy management system. The renovation is gradually carried out while maintaining the research function, and the final completion is scheduled in the fiscal year 2022.

The Tsukuba Research Laboratories is a core research center for drug discovery research in the neurology and oncology fields, which are our priority areas, and conducts drug discovery activities with the aim of contributing to global health including neglected tropical diseases. In addition, the Tsukuba Research Laboratories will also play a central role as a base for Data-Driven Drug Discovery & Development (5D drug discovery) to create a paradigm shift in drug discovery by digital technology. Through these initiatives, Eisai accelerates the drug discovery activities and is striving to further contribute to satisfy unmet medical needs and to improve the benefits to patients and their families.


About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
Public Relations Department
Eisai Co., Ltd. 
+81-(0)3-3817-5120


Dec 10, 2019 08:02 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2020 08:31 HKT/SGT
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
July 22, 2020 16:04 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
July 20, 2020 11:36 HKT/SGT
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
July 14, 2020 08:20 HKT/SGT
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
July 13, 2020 10:47 HKT/SGT
Eisai: Industry-Academia-Government Joint Development Agreement Aiming for Drug Discovery for Systemic Lupus Erythematosus by Practical Application of Toll-Like Receptor Research Concluded
July 9, 2020 11:20 HKT/SGT
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
July 9, 2020 11:11 HKT/SGT
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
July 8, 2020 13:33 HKT/SGT
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
July 8, 2020 13:16 HKT/SGT
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
July 6, 2020 08:33 HKT/SGT
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: